Lung Cancer Screening Software Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Lung Cancer Screening Software Market Trends and Insights

Rising Global Lung-Cancer Incidence & Expansion of LDCT Screening Programmes

Lung cancer remains the leading cause of cancer mortality worldwide, and aging populations, coupled with persistent smoking rates in emerging economies, keep incidence on an upward slope. U.S. Medicare’s 2022 eligibility expansion instantly brought an additional 6.4 million adults into the annual screening pool.^{[1]Centers for Medicare & Medicaid Services, “Lung Cancer Screening,” cms.gov} Germany’s HANSE trial and the United Kingdom’s Targeted Lung Health Check program have demonstrated early-stage detection rates above 70%, galvanizing European payers to evaluate nationwide roll-outs. China’s tier-1 cities have launched AI-enabled pilots that offset local radiologist shortages and create large-scale demand for automated registry tools. As these initiatives mature, software that quantifies nodules, tracks interval growth, and generates structured Lung-RADS reports becomes indispensable to meeting quality metrics.

AI/Deep-Learning Breakthroughs Improving Nodule-Detection Accuracy & Workflow

Convolutional neural-network models trained on multinational datasets are now sensitive to nodules ≥3 mm with ≥90% accuracy, slashing historical false-negative rates. The FDA cleared Qure.ai’s qXR-LN in Jan 2024 and qCT LN Quant in Aug 2024, both of which were validated across ethnically diverse cohorts to mitigate bias.^{[2]U.S. Food and Drug Administration, “510(k) Premarket Notification,” fda.gov} V5med’s Lung AI received clearance in Mar 2025, and AZmed’s AZnod followed in Dec 2025, signaling regulatory comfort with AI-assisted triage. Peer-reviewed studies show that AI can cut radiologist interpretation time by up to 40% while reducing false positives by 20-30%, allowing staff to focus on complex assessments.^{[3]Radiological Society of North America, “Radiology,” rsna.org} European CE marking under the Medical Device Regulation framework further broadens marketable geographies.

Government & Payer Reimbursement for Lung-Cancer Screening

Coverage policies dictate adoption velocity. Medicare reimburses annual LDCT without patient cost-sharing when providers complete shared decision-making visits and push structured results to CMS-approved registries. Germany funds screening under insurer pilot contracts, and Japan’s private payers began covering scans for high-risk adults in 2024. Australia’s 2025 benefit-schedule addition opened public funding, though eligibility remains narrower than in the United States. Conversely, many emerging markets still lack billing codes, forcing vendors to rely on hospital capital budgets rather than fee-for-service payments.

Cloud-SaaS Delivery Lowering CAPEX for Small & Mid-Size Providers

Subscription-based deployment removes six-figure up-front hardware fees and lets facilities pay only for active users and storage. GE HealthCare’s cloud-native PACS scales elastically, Philips and Mass General Brigham proved multi-vendor interoperability across 12 hospitals in 2025, and Siemens Healthineers’ AI-Rad Companion now updates models overnight through secure web portals. NIST Special Publication 1800-24 provides an encryption and audit-logging playbook that de-risks cloud connectivity compliance. As 5G backbones and hospital edge appliances mature, even rural imaging centers can adopt sophisticated algorithms without local servers.

High Implementation & PACS/RIS Integration Costs

Mid-size hospitals running legacy image archives frequently need middleware that translates DICOM tags, routes studies to cloud endpoints, and returns annotated images to radiologist worklists. Total integration outlays can exceed USD 500,000 once HL7 FHIR interfaces, firewall upgrades, and radiologist training are included. Vendors lacking ready connectors for dominant PACS brands must endure extended CIO vetting and custom builds that delay ROI. Temporary workflow slowdowns during go-live windows further discourage administrators who prioritize throughput over incremental improvements in accuracy.

Data-Privacy / Cyber-Security Compliance & Liability Exposure

Hospitals that send CT images to external AI servers must satisfy HIPAA’s encryption-in-transit rules and GDPR’s data-protection-impact-assessment mandates. In 2024, the U.S. HHS levied fines up to USD 1.5 million per violation category for gaps in business-associate agreements, while GDPR penalties can hit EUR 20 million or 4% of global turnover, whichever is higher. A spike in ransomware attacks on radiology networks prompted insurers to raise cyber-liability premiums and forced hospitals to conduct penetration testing before activating AI integrations. Vendors that store identifiers in low-sovereignty jurisdictions risk contract cancellations if breaches occur.

Segment Analysis

By Mode of Delivery: Cloud Dominance Reshapes Capital Planning

Cloud-based deployments held 52.91% of the lung cancer screening software market share in 2025 and are on track for a 12.07% CAGR to 2031. The lung cancer screening software market for cloud solutions is projected to grow over the forecast horizon, supported by pay-as-you-go subscriptions that appeal to community hospitals. Hospitals avoid local server purchases, and IT departments benefit from overnight model updates pushed by vendors such as Siemens Healthineers and Philips that guarantee the latest weights without manual patching. 5G backbone roll-outs and edge caching now mitigate latency concerns even for rural imaging centers. 

On-premise platforms remain necessary in jurisdictions with strict data localization rules or where chief information security officers prohibit external uploads. Web-based hybrids host inference engines on vendor servers but keep images on-site, offering a compliance middle ground. NIST’s SP 1800-24 blueprint helps institutions harden cloud endpoints and has shortened purchasing cycles by clarifying requirements for encryption, audit logging, and access controls. As CIOs refresh infrastructure over the next four years, hybrid cloud plus edge-appliance configurations are expected to dominate multi-site radiology groups.

Note: Segment shares of all individual segments available upon report purchase

By Product: Patient Navigation Modules Outpace Detection Software

Radiology and CADe engines commanded 36.73% of 2025 revenue, underscoring their role as the clinical backbone of the lung cancer screening software market. Yet registry-ready patient-navigation suites are growing 2.5 percentage points faster, reflecting CMS rules that tie payment to structured data submission. 

ACR’s 2024 Lung-RADS update spurred software revisions that integrate volumetric thresholds and track nodule growth across serial scans. Optellum’s Virtual Lung Clinic already bundles risk stratification, MDT dashboards, and patient portals, while Aidence’s Veye Lung Nodules exports one-click structured reports directly into electronic medical records. Hospitals that miss registry deadlines risk CMS penalties, making integrated navigation a compliance imperative.

By End User: Imaging Centers Scale Faster Than Hospitals

Hospitals generated 43.76% of 2025 revenue, reflecting their dominant scan volumes and in-house radiology teams. However, diagnostic imaging centers, the next-largest cohort, are growing at a 14.13% CAGR. Cloud subscriptions eliminate high up-front costs, making sophisticated AI affordable to independent centers that compete on service differentiation. Qure.ai’s qXR-LN and qCT LN Quant, cleared in 2024, are specifically designed for imaging centers that lack thoracic subspecialists but wish to market LDCT screening services. 

Oncology centers integrate screening pipelines with treatment-planning systems for seamless patient handoffs once biopsies confirm malignancy. Ambulatory surgical centers lag due to limited IT budgets and lower scan throughput. In China, Infervision’s InferRead CT Lung anchors rural county-hospital programs where subspecialty radiologists are scarce, offering a template for adoption in emerging markets. As value-based care contracts expand, all provider types must document detection rates and diagnostic timeliness, metrics that AI systems can automatically capture.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America captured 45.53% of 2025 revenue, buoyed by Medicare coverage that removes patient co-pays and by a vibrant AI startup ecosystem clustered around Boston, Silicon Valley, and Madison. Canada’s Ontario and British Columbia pilots showed promising early detection outcomes, although national guidelines remain pending. U.S. vendors often bundle software with scanner upgrades, accelerating refresh cycles. 

Europe ranked second in 2025, led by Germany’s insurer-funded pilots and the U.K.’s mobile CT fleets that visit underserved areas. CE-marked algorithms comply with the EU Medical Device Regulation, yet varying national reimbursement policies slow broad deployment, particularly in France and Spain. 

Asia-Pacific is the fastest-growing territory at a 13.93% CAGR through 2031, underpinned by China’s city-level pilots, Japan’s guideline inclusion, and India’s private-hospital initiatives. InferRead CT Lung installations across Chinese county hospitals demonstrate viability in lower-resource settings, while Australia’s 2025 benefit-schedule item catalyzed uptake among radiology groups. South Korea’s national insurance program added LDCT for high-risk adults in 2024, providing vendors with an early revenue stream. 

Middle East & Africa and South America remain nascent. Gulf states invest in high-end imaging for medical tourism but lack population screening mandates. Brazil and Argentina rolled out small pilots in 2025, yet face budget constraints that limit scale, suggesting a gradual revenue ramp into the next decade.